Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

Abstract Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health Service (NHS) perspective. Methods A linked-equat...

Full description

Bibliographic Details
Main Authors: Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs, Afisi S. Ismaila
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Chronic obstructive pulmonary disorder
Cost-effectiveness
Economic evaluation
Long-acting muscarinic antagonist
Online Access:http://link.springer.com/article/10.1186/s12962-018-0101-3

Internet

http://link.springer.com/article/10.1186/s12962-018-0101-3

Similar Items